PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer

Long Qian, Xin An, Miao Chen, Nan Wang, Silei Sui, Yixin Li, Changlin Zhang, Kaping Lee, Xiaonan Wang, Tian Tian, Yangxun Pan, Huijuan Qiu, Fang‐Yun Xie, Wuguo Deng, Fufu Zheng, Liru HeFrontiers in Oncology 2020 · DOI

TL;DR

This study identifies a novel molecular axis, PUF60/AURKA, that plays a critical role in the progression and malignancy of bladder cancer. The researchers found that PUF60, an RNA splicing factor, is highly expressed in bladder tumors and promotes cancer growth by upregulating AURKA, a known oncogene. This axis represents a promising new target for diagnostics and therapies in bladder cancer.

What Problem Does This Paper Address?

Bladder cancer is a significant global health concern, ranking as the sixth most common cancer in men. Despite advancements in diagnosis and treatment, predicting patient outcomes and therapy response remains challenging due to the limitations of current staging systems. This necessitates the discovery of new biomarkers that can accurately stratify patients and guide treatment decisions. While RNA splicing proteins are known to be involved in various cancers, their specific roles in bladder cancer development and progression have not been systematically elucidated. This paper aims to address this gap by investigating the role of RNA splicing proteins, specifically PUF60, in bladder cancer and identifying potential therapeutic targets.

Methods

The researchers employed a multi-faceted approach to investigate the PUF60/AURKA axis:

  • Bioinformatics Analysis: They analyzed publicly available datasets (TCGA, GEO) to identify differentially expressed RNA splicing proteins in bladder cancer tissues compared to normal tissues.
  • Cell Culture Experiments: Various human bladder cancer cell lines were used to study the effects of PUF60 knockdown and overexpression on cell viability, colony formation, and cell cycle progression.
  • Molecular Biology Techniques:
    • Western Blotting: Used to detect protein expression levels of PUF60 and AURKA.
  • qRT-PCR: Used to measure mRNA expression levels.
  • Luciferase Reporter Assay: Employed to investigate the transcriptional regulation of AURKA by PUF60, by testing the activity of different segments of the AURKA promoter.
  • Streptavidin-Agarose Pulldown Assay: Used to confirm the direct binding of PUF60 to the AURKA promoter.
  • Immunohistochemistry (IHC): Performed on bladder cancer tissue microarrays to assess PUF60 protein expression in tumor samples and correlate it with clinical phenotypes.
  • Statistical Analysis: Kaplan-Meier survival analysis was used to assess the prognostic value of PUF60 expression. Correlation analyses (Spearman rank) were performed to examine the relationship between PUF60 and AURKA expression.

Datasets

The study utilized several publicly available datasets for their analyses:

  • TCGA (The Cancer Genome Atlas): Used for initial identification of differentially expressed RNA splicing proteins and for analyzing PUF60 mRNA expression and its association with clinical characteristics and survival.
  • GEO (Gene Expression Omnibus): Multiple GEO datasets (GSE13507, GSE3167, GSE86411, GSE128192, GSE120736, GSE128959, GSE48276, GSE124305, GSE31684) were used to validate PUF60 and AURKA expression patterns and their correlations with clinical data and survival.
  • Oncomine Database: Utilized to further confirm the differential expression of PUF60 in bladder cancer tissues.
  • Tissue Microarrays: Commercially obtained tissue microarrays were used for immunohistochemical analysis of PUF60 protein expression.

Key Insights and Ideas

  • PUF60 as a Key Player in Bladder Cancer: The study firmly establishes PUF60 as a significantly upregulated RNA splicing factor in bladder cancer, distinguishing it from normal tissues. This finding is crucial as it highlights a potential driver of the disease.
  • PUF60's Link to Malignancy: Beyond just being elevated, high PUF60 expression is directly associated with more aggressive bladder cancer phenotypes, including basal-like subtypes, higher pathological grades, and advanced tumor stages. This suggests PUF60 isn't just a marker but actively contributes to the cancer's dangerous characteristics.
  • AURKA as a Direct Downstream Target: The research provides strong evidence that PUF60 directly regulates AURKA expression by binding to its promoter. This mechanistic insight is key to understanding how PUF60 drives cancer progression.
  • The PUF60/AURKA Axis as a Prognostic Indicator: The combined high expression of PUF60 and AURKA is linked to poorer patient survival, making this axis a potential tool for predicting patient outcomes.
  • Therapeutic Potential: The findings suggest that targeting either PUF60 or AURKA, or their interaction, could be a viable strategy for developing new bladder cancer therapies.

Key Results

  • PUF60 Overexpression: PUF60 mRNA and protein were significantly overexpressed in bladder cancer tissues compared to normal tissues across multiple datasets.
  • Association with Malignant Phenotypes: High PUF60 expression was significantly associated with basal-like molecular subtypes, higher pathological grades, and advanced T stages of bladder cancer.
  • Prognostic Value: Patients with high PUF60 mRNA expression showed significantly shorter overall survival in TCGA data and several GEO datasets.
  • Functional Impact: Knockdown of PUF60 in bladder cancer cells inhibited cell viability and colony formation, while overexpression promoted these processes. PUF60 also influenced cell cycle progression.
  • AURKA Regulation: PUF60 directly binds to the AURKA promoter and upregulates its transcription and expression.
  • Rescue Experiments: Overexpression of AURKA partially reversed the inhibitory effects of PUF60 knockdown on cell growth, and AURKA inhibitors reversed the promotive effects of PUF60 overexpression.
  • Correlation: A significant positive correlation was observed between PUF60 and AURKA expression in bladder cancer tissues.

Limitations and Future Work

  • In Vivo Validation: The authors acknowledge that while in vitro experiments demonstrate PUF60's oncogenic role, future animal experiments are needed to validate these findings in vivo.
  • Mechanistic Nuances: The exact mechanism by which PUF60 regulates AURKA expression is still being explored. While direct promoter binding is shown, PUF60 is not a transcription factor, suggesting it might interact with other machinery components or transcription factors.
  • RNA Splicing Function: The study did not fully elucidate whether PUF60's RNA splicing functions are involved in AURKA regulation.
  • Partial Rescue: The fact that AURKA overexpression only partially rescued the effects of PUF60 knockdown suggests that PUF60 may have other downstream targets or functions contributing to bladder cancer progression.
  • Future Directions: The authors propose investigating PUF60's role in other bladder cancer processes like migration and invasion, exploring its interaction with other components of the transcription machinery, and identifying other downstream targets of the PUF60/AURKA axis.

Summary updated

Abstract

Abnormal expression or mutation of RNA splicing proteins are widely observed in human cancers. Here, we identified poly(U) binding splicing factor 60 (<i>PUF60</i>) as one of the most differentially expressed genes out of 97 RNA splicing proteins between normal and bladder cancer tissues by bioinformatics analysis of TCGA bladder cancer expression data. The expression of <i>PUF60</i> was significantly higher in tumor tissues, while high <i>PUF60</i> expression was associated with malignant phenotypes of bladder cancer and shorter survival time. Moreover, we identified aurora kinase A (<i>AURKA</i>) as a new downstream target of <i>PUF60</i> in bladder cancer cells. <i>PUF60</i> knockdown significantly inhibited cell viability and colony formation capacity in bladder cancer cells, whereas <i>AURKA</i> overexpression reversed this inhibition effect. Overexpression of <i>PUF60</i> significantly promoted cell viability and colony formation in bladder cancer cells, while treatment with <i>AURKA</i> specific inhibitor reversed this promotive effect. Mechanistically, <i>PUF60</i> specifically bound to the <i>AURKA</i> promoter, thereby activating its transcription and expression. Furthermore, we showed that there was a significant positive correlation between <i>PUF60</i> and <i>AURKA</i> expression in bladder cancer tissues, and <i>PUF60</i> and <i>AURKA</i> expression contributed to tumor progression and malignant phenotypes in the patients with bladder cancer. Collectively, these results indicate that the <i>PUF60/AURKA</i> axis plays a key role in regulating tumorigenesis and progression of bladder cancer, and may be a potential prognostic biomarker and therapeutic target for bladder cancer patients.
BibTeX
@inproceedings{qian2020puf,
  author = {Long Qian and Xin An and Miao Chen and Nan Wang and Silei Sui and Yixin Li and Changlin Zhang and Kaping Lee and Xiaonan Wang and Tian Tian and Yangxun Pan and Huijuan Qiu and Fang‐Yun Xie and Wuguo Deng and Fufu Zheng and Liru He},
  title = {{PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.568015},
}
Figure